. . "Vansil"@en . . . . . . . . . . "1-2.5 hours"@en . . . . . . "Well absorbed orally"@en . . . . . "An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia, 31st ed, p121)"@en . . . . "Mansil"@en . . "# Filho RP, de Souza Menezes CM, Pinto PL, Paula GA, Brandt CA, da Silveira MA: Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs. Bioorg Med Chem. 2007 Feb 1;15(3):1229-36. Epub 2006 Nov 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17134907"@en . . "Oxamniquine"@en . "\"DrugSyn.org\":http://www.drugsyn.org/Oxamniquine.htm"@en . "For treatment of Schistosomiasis caused by Schistosoma mansoni"@en . . . . . . . . . . . . . . "Oxamniquine may associate with an irreversible inhibition of the nucleic acid metabolism of the parasites. A hypothesis has been put forth that the drug is activated by a single step, in which a schistosome sulfotransferase enzyme converts oxamniquine into an ester (probably acetate, phosphate, or sulfate). Subsequently, the ester spontaneously dissociates, the resulting electrophilic reactant is capable of alkylation of schistosome DNA."@en . . "Schistosoma mansoni"@en . . "21738-42-1"@en . . . "approved"@en .